4 results about "Clinical marker" patented technology

The application provides a clinical marker screening method and system after metabolic response typing and application. Specifically, according to the change of metabolic indexes of normal weight people and overweight / obese people before and after meals, three clusters based on respiratory quotient (RQ) are found; the fasting fat oxidation capacity, postprandial metabolic response and postprandial blood glucose response of people belonging to different clusters also have different dynamic change patterns. In addition, key biomarkers distinguishing the three clusters are also found; the prediction model constructed by using the key biomarkers can accurately divide the subjects into three RQ clusters and can be used for predicting the results of weight loss intervention and life intervention guidance. The system constructed according to the clinical markers of the application has high sensitivity and accuracy, the indexes used are easy to obtain, and has good clinical application prospect.

The invention belongs to the technical field of biomedical detection, and discloses a biomarker for predicting or diagnosing diabetic peripheral neuropathy and application of the biomarker, and the biomarker comprises GREM2 and HPD. The biomarker disclosed by the invention is high in sensitivity, strong in specificity, capable of accurately identifying DPN and reliable in detection result, the AUC value of combined diagnosis of two differential proteins reaches 0.86, and the biomarker is remarkably superior to an existing clinical marker. When the biomarker is combined with clinical markers Age, BMI, T2DM daughter and HbA1c for use, the AUC value of the biomarker can reach 0.95. When the biomarker is applied, only a small number of blood samples of a patient are needed, the detection method is simple, convenient and rapid, the professional requirement is not high, and the biomarker is suitable for clinical popularization.

Provided are methods of determining risk for chronic stress and stroke. More specifically, provided is an early prognostic index that can be used to predict chronic stress and stroke risk. There is provided a method of evaluating the risk of developing chronic stress and stroke, the method including obtaining a biological sample from an individual; measuring the levels of a set of biomarkers in the biological sample obtained from the individual; measuring the levels of a set of clinical markers of the individual; using a computer to programmatically generate an index based on the levels of biomarker in the biological sample obtained from the individual in combination with levels of the individual's clinical marker; and using the index to identify a likelihood that the individual will experience chronic stress and stroke.

The present application relates to the biomedical field, and particularly to a clinical marker for monitoring CRS progress after CAR-T treatment and application thereof, the cytokine release syndrome (CRS) progress is judged by the expression of apolipoprotein A-1, so that effective treatment can be carried out and new treatment methods can be developed. The present application discloses APOA1 for the first time to monitor the cytokine release syndrome (CRS) progress after CAT-T treatment, and it is found through mass spectrometry and biochemical detection that APOA1 is expressed the lowest when the inflammation of the cytokine release syndrome (CRS) patient is the most serious, and with the recovery of the inflammation, its expression is also gradually recovered to the pre-treatment, and the cytokine release syndrome (CRS) progress of the patient has good consistency. These results suggest that APOA1 is an important clinical indicator for monitoring the cytokine release syndrome (CRS).